Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline
This synopsis distills KDIGO's updated 2024 guideline for diagnosing and managing chronic kidney disease in adults and children, highlighting new recommendations on GFR estimation, individualized risk-based care, and broader use of SGLT2 inhibitors and statins.
Background
KDIGO updated its prior CKD guideline based on systematic review of evidence through July 2023, addressing evaluation, risk stratification, and management of CKD in adults and children not receiving kidney replacement therapy.
Key findings
The guideline's 28 recommendations and 141 practice points emphasize cystatin C for GFR assessment, point-of-care testing in remote settings, individualized risk-based prediction of kidney failure, SGLT2 inhibitors for CKD with or without diabetes, and statins for adults over 50 with CKD.
Clinical implications
Clinicians should incorporate cystatin C-based eGFR where available, consider SGLT2 inhibitor therapy more broadly across CKD phenotypes, and apply individualized risk prediction rather than staging alone to guide referral and treatment intensity.
Category
KDIGO
Source
Annals of Internal Medicine
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.